Collaboration

Advancing non-viral cell engineering through joint scientific innovation

• Joint development of next-generation CAR-T, CAR-NK, and gene-editing strategies enabled by CellShot® ND-FFT.
• Technology validation and process optimization through collaboration with leading academic and medical research centers.
• Co-publications, conference presentations, and peer-reviewed validation studies supporting scientific credibility and translational readiness.

Bridging laboratory innovation to clinical translation

• Hospital-based collaborations supporting early-phase and investigator-initiated clinical studies.
• Integration of CellShot® systems and Proliva™ workflows into clinical research pipelines for non-viral gene delivery.
• Close collaboration with clinicians to optimize manufacturability, consistency, and post-transfection cell fitness for clinical use.

Flexible partnership models for scalable cell therapy manufacturing

• Strategic co-development partnerships with biotech and pharmaceutical companies to advance next-generation cell and gene therapies.
• Flexible licensing and collaboration models, including non-exclusive access and indication- or territory-specific exclusivity.
• Integration of PFEP™-based non-viral delivery into proprietary cell therapy platforms to overcome manufacturing and scalability bottlenecks.

Manufacturing-ready integration for GMP environments

• GMP-compatible PFEP™ modules and consumables designed for seamless integration into closed-system manufacturing workflows.
• Regulatory-aligned support leveraging FDA DMF registration and global regulatory pathways.
• Technology transfer, process documentation, and on-site training to ensure reproducibility, compliance, and operational readiness.

Extending ND-FFT architectures beyond current cell therapy paradigms

CellShot's ND-FFT platform is designed as a modality-agnostic, non-viral engineering framework, enabling controlled delivery and protection across emerging biological systems.

• Expansion of PFEP™ and Proliva™ architectures into future therapeutic modalities, including mRNA-based systems, protein delivery, and selected cell-free or hybrid bioprocessing platforms—where precise, non-destructive delivery is critical.
• Exploration of new platform applications in synthetic biology, regenerative medicine, and next-generation biomanufacturing, with a focus on scalability, repeatability, and process control.
• Development of next-generation non-viral workflows that bridge novel modalities with manufacturing-ready design principles, ensuring alignment with regulatory, CMC, and GMP requirements.

CellShot approaches future modalities not as experimental extensions, but as engineered platforms—built to translate from concept to manufacturing.